Drug Profile


Alternative Names: SB 332235

Latest Information Update: 01 Dec 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Interleukin 8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 01 Dec 2004 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 01 Dec 2004 Discontinued - Preclinical for Psoriasis in United Kingdom (PO)
  • 12 Oct 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics and Respiratory Tract Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top